---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-281522"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:50:21.328584+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# TuHURA reports Q3 R&D $4.9M, cash burn $22.1M; Phase 3 MCC trial underway

## Summary
- Phase 3 IFx-2.0 trial for MCC under SPA enrollment ongoing; topline results expected Q1 2027.
- R&D expenses $4.9M (Q3 2025) vs $2.9M (Q3 2024); 9-month net cash outflow $22.1M vs $12.1M.
- DOR technology selected for oral presentation at ASH 2025 Annual Meeting in December.
- Appointed Dr. Michael Turner as Vice President of Immunology in November 2025.
- Filed $50M ATM facility in November 2025; not yet effective.

## SEC filing metadata
- accession: 0001193125-25-281522
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000119312525281522/0001193125-25-281522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000119312525281522/hura-20251114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-281522
- JSON: https://secwatch.observer/filing/0001193125-25-281522.json
- Plain text: https://secwatch.observer/filing/0001193125-25-281522.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.